[go: up one dir, main page]

WO2006030306A3 - Methodes et compositions pour le traitement du syndrome premenstruel (pms) et d'un trouble dysphorique premenstruel (pmdd) - Google Patents

Methodes et compositions pour le traitement du syndrome premenstruel (pms) et d'un trouble dysphorique premenstruel (pmdd) Download PDF

Info

Publication number
WO2006030306A3
WO2006030306A3 PCT/IB2005/002769 IB2005002769W WO2006030306A3 WO 2006030306 A3 WO2006030306 A3 WO 2006030306A3 IB 2005002769 W IB2005002769 W IB 2005002769W WO 2006030306 A3 WO2006030306 A3 WO 2006030306A3
Authority
WO
WIPO (PCT)
Prior art keywords
premenstrual
pindolol
treating
dysphoric disorder
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/002769
Other languages
English (en)
Other versions
WO2006030306A2 (fr
WO2006030306A8 (fr
Inventor
Timothy Dinan
Peter Daly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeuroCure Ltd
Original Assignee
NeuroCure Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NeuroCure Ltd filed Critical NeuroCure Ltd
Priority to US11/663,075 priority Critical patent/US20080262071A1/en
Priority to JP2007531860A priority patent/JP2008513430A/ja
Priority to AU2005283829A priority patent/AU2005283829A1/en
Priority to EP05779646A priority patent/EP1793818A2/fr
Publication of WO2006030306A2 publication Critical patent/WO2006030306A2/fr
Publication of WO2006030306A3 publication Critical patent/WO2006030306A3/fr
Anticipated expiration legal-status Critical
Publication of WO2006030306A8 publication Critical patent/WO2006030306A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

Selon l'invention, on a découvert que le pindolol constitue un traitement hautement efficace pour le PMS et/ou le PMDD. L'invention concerne généralement des méthodes et des compositions pour traiter et/ou pour prévenir le PMS, ou des symptômes associés au PMS, notamment une tension prémenstruelle ou une diyphorie prémenstruelle. Les méthodes et les compositions de l'invention concernent également l'utilisation de pindolol, un bloqueur bêta-adrénergique connu, combiné à des contraceptifs connus.
PCT/IB2005/002769 2004-09-17 2005-09-19 Methodes et compositions pour le traitement du syndrome premenstruel (pms) et d'un trouble dysphorique premenstruel (pmdd) Ceased WO2006030306A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US11/663,075 US20080262071A1 (en) 2004-09-17 2005-09-19 Pindolol for the Treating Premenstrual Syndrome and Premenstrual Dysphoric Disorder
JP2007531860A JP2008513430A (ja) 2004-09-17 2005-09-19 月経前症候群および月経前不快気分障害の処置のためのピンドロール
AU2005283829A AU2005283829A1 (en) 2004-09-17 2005-09-19 Pindolol for the treating premenstrual syndrome and premenstrual dysphoric disorder
EP05779646A EP1793818A2 (fr) 2004-09-17 2005-09-19 Pindolol pour le traitement du syndrome et du trouble dysphorique premenstruel

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US61061004P 2004-09-17 2004-09-17
US60/610,610 2004-09-17
US65494305P 2005-02-23 2005-02-23
US60/654,943 2005-02-23
US68671805P 2005-06-01 2005-06-01
US60/686,718 2005-06-01

Publications (3)

Publication Number Publication Date
WO2006030306A2 WO2006030306A2 (fr) 2006-03-23
WO2006030306A3 true WO2006030306A3 (fr) 2006-09-08
WO2006030306A8 WO2006030306A8 (fr) 2007-10-04

Family

ID=35457136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002769 Ceased WO2006030306A2 (fr) 2004-09-17 2005-09-19 Methodes et compositions pour le traitement du syndrome premenstruel (pms) et d'un trouble dysphorique premenstruel (pmdd)

Country Status (4)

Country Link
EP (1) EP1793818A2 (fr)
JP (1) JP2008513430A (fr)
AU (1) AU2005283829A1 (fr)
WO (1) WO2006030306A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021509A2 (fr) 1998-10-15 2000-04-20 Imperial College Innovations Limited Methodes therapeutiques
GB0624282D0 (en) * 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
JP2012526832A (ja) * 2009-05-13 2012-11-01 スノビオン プハルマセウトイカルス インコーポレイテッド トランスノルセルトラリン及びセロトニン受容体１ａ作動剤／拮抗剤を含む組成物及びその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0714663A2 (fr) * 1994-11-28 1996-06-05 Eli Lilly And Company Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
WO1999002142A2 (fr) * 1997-07-11 1999-01-21 Smithkline Beecham P.L.C. Nouvelle composition
US20020165263A1 (en) * 2001-02-20 2002-11-07 T.G. Dinan Treatment of fibromyalgia and related fatigue syndromes using antagonists or paritcal agonists of 5HT1a receptors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0714663A2 (fr) * 1994-11-28 1996-06-05 Eli Lilly And Company Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
WO1999002142A2 (fr) * 1997-07-11 1999-01-21 Smithkline Beecham P.L.C. Nouvelle composition
US20020165263A1 (en) * 2001-02-20 2002-11-07 T.G. Dinan Treatment of fibromyalgia and related fatigue syndromes using antagonists or paritcal agonists of 5HT1a receptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PARKER P D: "Premenstrual syndrome.", AMERICAN FAMILY PHYSICIAN. 1 NOV 1994, vol. 50, no. 6, 1 November 1994 (1994-11-01), pages 1309 - 1317 , 13, XP008062633, ISSN: 0002-838X *
RAUSCH J L ET AL: "ATENOLOL TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER", JOURNAL OF AFFECTIVE DISORDERS, vol. 15, no. 2, 1988, pages 141 - 147, XP002375780, ISSN: 0165-0327 *

Also Published As

Publication number Publication date
WO2006030306A2 (fr) 2006-03-23
EP1793818A2 (fr) 2007-06-13
JP2008513430A (ja) 2008-05-01
WO2006030306A8 (fr) 2007-10-04
AU2005283829A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
WO2010126626A3 (fr) Inhibiteurs à mécanisme double pour le traitement de maladie
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
PH12013500355A1 (en) Engineered anti-tslp antibody
WO2008097640A3 (fr) Composés à base de triazole modulant l'activité de hsp90
WO2005063232A8 (fr) Traitement de l'obesite et du syndrome metabolique avec des derives de tanshinone augmentant l'activite metabolique
TNSN07111A1 (en) Preparation and use of biphenyl-4-yl- carbonylamino acid derivatives for the treatment of obesity.
WO2007046102A3 (fr) Methodes destinees a traiter l'hyperhidrose
WO2009052431A3 (fr) Agents de liaison au cd19 et utilisations de ceux-ci
WO2007139967A3 (fr) Composés de triazole modulant l'activité de hsp90
WO2007139955A3 (fr) Composés de triazole qui modulent l'activité de la hsp90
WO2007139968A3 (fr) Composés de triazole qui modulent l'activité de la hsp90
WO2007094819A8 (fr) Dérivés de triazole modulant l'activité de hsp90
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
WO2008021210A3 (fr) Méthodes et compositions pour le traitement de troubles neurodégénératifs
WO2008070670A3 (fr) Formulations de topiramate à libération immédiate améliorées
WO2007075439A3 (fr) Compositions et methodes pour traiter l'obesite et des troubles metaboliques associes
TW200732296A (en) Novel compounds
MX2009008135A (es) Uso de histidinato de cromo para tratamiento de alteraciones cardiometabolicas.
TW200640454A (en) Method for treating obesity
WO2004112786A3 (fr) Traitement de la depression et d'autres troubles affectifs
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
WO2008121386A3 (fr) Procédés de traitement de troubles intestinaux
WO2009009034A3 (fr) Procédées et compositions utiles dans le traitement de la mucosite
WO2006102061A3 (fr) Methode de reduction de la calcification
WO2007149875A8 (fr) Compositions et procédés pour traiter, prévenir et/ou faire régresser le diabète de type 1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005779646

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007531860

Country of ref document: JP

Ref document number: 2005283829

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005283829

Country of ref document: AU

Date of ref document: 20050919

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005283829

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005779646

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11663075

Country of ref document: US